On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...